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Abstract
Purpose: Oncologists avoid prognostic discussions due to concerns about increasing patients’ anxiety or
depression. We sought to determine if perceived prognosis or extent of prognostic discussions predicted anxiety
or depression and whether prognostic discussions moderated the relationship between prognosis and anxiety or
depression.
Methods: Men with advanced cancer and their oncologists estimated the likelihood of survival at 6 months and
reported extent of prognostic discussions. Anxiety and depression were measured by the Hospital Anxiety and
Depression Scale (HADS).
Results: Men who died within 6 months reported higher scores on depression but not anxiety. Men who
estimated a lower (10%–75%) likelihood of surviving at least 6 months were more depressed and anxious than
men who estimated a higher ( > 90%) likelihood of survival. A similar relationship was seen with oncologists’
prognostications. Men who reported having had full prognostic discussions with their oncologist had less
depression compared with men who reported having had brief or no discussions. Men for whom the oncologists
reported a full discussion had greater anxiety. The relationships between patient-perceived prognosis and
depression or anxiety were moderated by extent of prognostic discussions as reported by the patient or on-
cologist, respectively.
Conclusion: Full prognostic discussions are associated with less depression among men who perceive a poor
prognosis. Anxiety is increased in men if the oncologists report a full discussion. Oncologists should engage in
prognostic discussions but assess for increased anxiety to facilitate coping with advanced cancer.
Introduction
Oncologists frequently avoid explicit discussions oflife expectancy or alternatives to chemotherapy,1–3 are
reluctant to discuss hospice and resuscitation preferences,4
and make more optimistic rather than pessimistic statements
in consultations.5 Patients with advanced cancer may conse-
quently choose to receive aggressive treatment near the end
of life rather than palliative care due to overly optimistic
perceptions of life expectancy or the benefit of aggressive
treatment.6–7 One explanation for incomplete prognostic dis-
cussions between patients and oncologists is oncologists’
concerns that such discussions may increase anxiety or de-
pression in patients with advanced cancer. These concerns
seem reasonable given the prevalence of anxiety or depression
in people with cancer8–10 and the correlation with disease
stage in some11–13 but not all studies.14–15 However, the ma-
jority of patients with advanced cancer express clear prefer-
ences for honest prognostic disclosure.16 Furthermore, people
with advanced cancer who discussed preferences for end-
of-life care with their oncologists were more likely to receive
less aggressive medical care and have improved quality of
life.17–18
Given the importance of prognostic disclosure to shared
decision making, there is a critical need to better understand
the relationships between prognostic discussions, perception
of prognosis, and anxiety or depression. Thus, we asked two
research questions in a cross-sectional study of men with
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advanced cancer: (1) are patient anxiety and depression re-
lated to actual survival, patients’ perceptions of prognosis,
oncologists’ perceptions of prognosis, or extent of prognostic
discussions?; and (2) does patient- or oncologist-reported
extent of prognostic discussion moderate the relationship
between patients perceptions of prognosis and anxiety or
depression? We were specifically interested in men because
gender influences psychological responses to illness.19–21
Methods
Study sample and procedures
All study procedures were approved by the institutional
review board. Patients with metastatic cancers for which there
was no curative therapy and who were treated at Indiana
University Simon Cancer Center by one of four collaborating
medical oncologists between January and December 2008
were approached in the clinic. Eligibility criteria included: (1)
men greater than 18 years of age; (2) at least one prior visit
with the oncologist; (3) a life expectancy of greater than 3
months; and (4) ability to provide informed consent in
English. Consented patients were given a study folder con-
taining the survey and a self-addressed, stamped envelope.
Patients who returned surveys were given a $25 gift card. The
treating oncologists completed surveys after the encounter.
Outcome variables. Anxiety and depression were
measured by the Hospital Anxiety and Depression Scale
(HADS). The HADS is a 14-item scale that consists of two 7-
item subscales.22
Predictor variables. Demographic and disease-related var-
iables: Patients provided information about age, education,
income, race, ethnicity, marital status, employment status,
living arrangements, and health insurance. The project man-
ager abstracted the type of cancer, whether or not the patient
was currently receiving chemotherapy, and the current status
of disease (remission, stable, or progressive) from the medical
record.
Overall survival (OS) from study enrollment: The OS from the
date of study enrollment was calculated using information
available through June 2010.
Patient and oncologist perceptions of prognosis: Patients and
their oncologists estimated the likelihood of the patient being
alive in 6 months given the current plan of care, by selecting
one of the following response categories: greater than 90%,
about 75%, about 50%, about 25%, less than 10%, or don’t
know. Due to small number of responses in the categories other
than ‘‘greater than 90%,’’ especially for patients, we dichoto-
mized perceived prognosis into greater than 90% and 75% or
less for subsequent bivariate and regression analyses (Table 1).
This is consistent with the analysis of Weeks and colleagues.7
Extent of prognostic discussions: Patients were asked to in-
dicate the extent of discussions about life expectancy by
choosing one of the following statements: (1) We have not
discussed my life expectancy because I do not want to discuss
the information; (2) We have not discussed my life expectancy
because my medical oncologist has not offered to have the
discussion; (3) We have briefly discussed my life expectancy;
and (4) We have discussed my life expectancy and I feel fully
informed about what I might expect. No patient selected
Table 1. Associations between Depression or Anxiety Scores and Survival or Prognosis
HADS Subscale
Depression Anxiety
n Mean SD P* ES Mean SD P* ES
Survival past 6 months
Yes 67 3.8 3.0 0.019 - 0.66 5.5 3.8 0.463 NA
No 15 5.9 3.9 6.3 3.6
Patient survival estimate, 6 months








90% or greater (2) 54 3.7 3.2 4.9 3.5
Don’t know (3) 16 3.3 2.7 5.5 3.7
Oncologist survival estimate, 6 months
75% or less 55 4.7 3.4 0.027 0.53 6.2 3.9 0.023 0.51
90% or greater 30 3.0 2.7 4.3 3.3
Don’t know 0 – – – –
Patient-reported extent of prognostic discussion
None (1) 22 4.5 3.3 0.050 0.56 6.6 3.3 0.318 NA
Brief (2) 35 4.7 3.6 5.1 4.0
Full (3) 27 2.8 2.4 5.3 3.6
Oncologist-reported extent of prognostic discussion
None 9 5.8 3.5 0.240 NA 5.3 3.8 0.967 NA
Brief 41 4.0 3.4 5.6 3.4
Full 35 3.7 3.0 5.5 4.2
*P= p value from the t test for two independent groups, and from ANOVA omnibus F test for three independent groups. For variables with
three groups, the group number (1, 2, and 3) is reported in parentheses, and if the omnibus test was significant ( p < 0.05) then post hoc
comparisons between the pairs of the groups were tested and any significant pair-wise comparisons ( p< 0.05) are shown using the group
numbers [e.g., (1)> (2)]. ES denotes effect size. The effect size was determined with the use of Cohen’s d statistic; an effect size of 0.20 is small,
0.50 moderate, and 0.80 large. SD denotes standard deviation.
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statement 1, so there were three response categories. The
wording of the oncologists’ survey was complementary.
Statistical analyses
We summarized patient demographics and disease-related
variables. Data were examined to ensure that normality and
constant variance assumptions were appropriate. For Research
Question 1, associations between categorical predictors and
outcomes of anxiety and depression were tested with inde-
pendent samples t tests for binary predictors and analysis
of variances (ANOVAs) for predictors with three categories.
Family-wise Type I error was controlled by adjusting alpha for
multiple comparisons. Specifically, significant omnibus tests
for ANOVAs were followed up with post hoc pair-wise tests
using the protected version of Fisher’s Least Significant Dif-
ference. Linear regression models were then used to examine
the unique associations between the main predictors of interest
(perceived prognosis and extent of discussion) and outcomes
while controlling for potentially confounding covariates.
For Research Question 2, moderation effects were assessed
by using linear regression models to examine interaction
terms between perceived prognosis variables and perceived
prognostic discussion variables. A significant interaction was
followed by analysis of ‘‘simple effects’’ by estimating sepa-
rate models for each category of extent of discussion. Inter-
action tests were adjusted for multiple comparisons.
Specifically, omnibus tests were adjusted using the false dis-
covery rate method, and subsequent pair-wise tests from the
‘‘simple effect’’ analyses were further adjusted using the
protected version of Fisher’s Least Significant Difference.
To understand the magnitude of effects, Cohen’s d effect
size was computed for Research Questions 1 and 2 as the
difference between two groups on their unadjusted (bivariate
analyses) or adjusted (regression analyses) outcome means,
divided by the pooled standard deviation.23
Results
Of the 114 men approached, 113 (99%) consented to partic-
ipate and 86 men (76%) returned completed surveys; their
characteristics are summarized in Table 2. The median age was
60.4 years (range 23.8–81.3 years). The most common cancers
were gastrointestinal (34.9%) or sarcomas (25.6%). At the time
of enrollment, 53 (61.6%) men were receiving chemotherapy.
Sixty-four (74.4%) had stable disease; the remainder had pro-
gressive disease. The median OS was 11.9 months (Fig. 1).
There were no differences in age, OS, or diagnoses between the
men who completed the survey and the 27 men who did not.
Depression and anxiety scores are summarized in Table
2.The mean (standard deviation) scores for the depression and
anxiety subscales were 4.1 (3.2) and 5.5 (3.8), respectively.
Fourteen men (16%) scored greater than 7 on the depression
subscale and 24 (28%) men scored greater than 7 on the anx-
iety subscale suggesting a depressive or anxiety state.
Research Question 1: Are patient anxiety or
depression related to actual survival, patient- or
oncologist-perceived prognosis, or reported
extent of prognostic discussions?
There were no significant correlations between demo-
graphic and disease-related variables including type of cancer
listed in Table 2 or enrolling medical oncologist and anxiety or
depression (data not shown). The results for other variables
are summarized in 12 along with calculated effect sizes that
range from 0.51 to 0.86, which are moderate to large.23 In
addition, it has been proposed that 0.36 or greater is a clini-
cally meaningful effect size for psychological interventions on
anxiety or depression in people with cancer.24 Men who died
within 6 months of enrollment reported more symptoms of
depression than men who were still alive ( p = 0.019). No dif-
ference was observed for anxiety.
As summarized in Table 1, the majority (63%) of men
perceived a 90% or greater likelihood of surviving past 6
Table 2. Patient (n = 86) Demographics, Disease
and Treatment Status, Survival, and HADS Scores
Characteristic No. of patients %
Demographic





Hispanic or Latino 2 2.4
Marital status




With other people 77 90.6
Income
£ $50,000 per year 32 40.5
> $50,000 per year 47 59.5
Education
High school degree or less 27 31.8
Some college 21 24.7
College graduate 15 17.7
Some graduate or












Receiving chemotherapy 53 61.6
Not receiving chemotherapy 32 37.2
Survival
Dead at £ 6 months 15 18.3
Dead at £ 12 months 35 42.7
Median overall survival, ( IQR) 11.9 (7.1–17.7 months)
Hospital Anxiety and Depression Scale (HADS)
Depression subscale
(mean – std. deviation)
4.1 – 3.2
Anxiety subscale
(mean – std. deviation)
5.5 – 3.8
IQR, interquartile range.
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months; 16 (18%) responded they ‘‘don’t know.’’ Fifteen pa-
tients (17%) who perceived a lower likelihood of survival
(75% or less) at 6 months experienced more depression and
anxiety (omnibus p= 0.028 and 0.021, respectively). Pair-wise
comparisons showed that men who perceived a lower likeli-
hood of surviving past 6 months had more depressive
symptoms than those who reported higher (90% or greater)
likelihood of survival ( p< 0.05). In addition, men who per-
ceived a lower likelihood of survival had higher depression
scores than those who reported they ‘‘don’t know.’’ Pair-wise
comparisons demonstrated that the mean anxiety score was
significantly higher for men who perceived a lower likelihood
of survival beyond 6 months. Similarly, mean depression and
anxiety scores were higher for men whose oncologists re-
ported a lower likelihood of survival at 6 months.
Twenty-two men (26%) reported having had no prognostic
discussions with their oncologists. The extent of prognostic
discussion was inversely associated with increased levels of
depression (omnibus p = 0.050). Pair-wise comparisons dem-
onstrated a marginally significant difference between brief
and full discussions ( p= 0.054). In an exploratory analysis, we
compared brief or no discussion with full discussions; men
who reported having had a full discussion had significantly
lower depressive symptoms ( p = 0.015; effect size [ES] = 0.56).
There was no association between anxiety and patient-
perceived extent of prognostic discussions. In addition, on-
cologist-reported extent of discussion was not associated with
levels of depression or anxiety.
Linear regression was used to assess the relationships be-
tween perceived prognosis, reported extent of prognostic
discussions, and anxiety or depression, controlling for the
potentially confounding effects of age and whether or not the
patient survived past 6 months. Age was controlled for be-
cause of its relevance to patient-physician communication
and treatment preferences. Survival was controlled for be-
cause of the possible relationships between anxiety or de-
pression as life is ending. Regression results demonstrated
three findings. First, the bivariate relationships remained
significant for prognosis and extent of discussion, after ad-
justing for age and survival. Second, both patient-perceived
prognosis and patient-perceived extent of discussion were
unique predictors of depression after adjusting for each other,
and for age and survival. Third, the two patient-perceived
prognostic pair-wise comparisons, which were not quite sig-
nificant in the bivariate analyses, were significant in the
models. Specifically, the mean depression score was signifi-
cantly higher among men who reported having no discussion
with their oncologist (versus full, p = 0.028) or only a brief
discussion (versus full, p= 0.020). Those who perceived they
had a worse prognosis had significantly higher depression
than those who perceived a better prognosis, after adjusting
for patient-perceived prognosis, age, and survival (75% or less
versus > 90%, p = 0.036).
Research Question 2: Does patient- or oncologist-
reported extent of prognostic discussion moderate
the relationship between patient-perceived
prognosis and anxiety or depression?
We were specifically interested in whether the relationship
between perceived prognosis and anxiety or depression was
dependent on the extent of prognostic discussions. Because
bivariate analyses showed a significant difference on de-
pression scores between men who reported full discussions
versus no or brief discussions, and because the oncologist-
perceived ‘‘no discussion’’ category was sparse, we examined
a two-level variable (no or brief versus full), in addition to the
three-level variable (none, brief, full). Both of these variables
were used when examining interactions between patient
perceptions of prognosis and patient- or oncologist-reported
extent of prognostic discussions. A total of eight interactions
were tested (three-level/two-level discussion crossed with
patient/MD discussion crossed with anxiety/depression).
Two significant interactions were found after adjusting for
multiple comparisons (Table 3). The first interaction was ob-
served between depression and patients’ estimated likelihood
of survival at 6 months and their reported extent of prognostic
discussion. Among patients who reported a brief or no dis-
cussion, those who perceived a worse prognosis had higher
depressive symptoms (omnibus p = 0.011). Conversely,
among patients who reported having had a full discussion
about prognosis, there was no difference in depression by
perceived prognosis. The second interaction involved patients’
anxiety levels, their perceived prognosis, and oncologist-
reported extent of prognostic discussion. The mean anxiety
score was greater for patients who reported a lower likelihood
of survival beyond 6 months if the oncologist reported having
had a full discussion (omnibus p= 0.002). There was no dif-
ference in mean anxiety scores for patients whose oncologists
reported having had no or only brief discussions.
Discussion
Men with advanced cancer who survived less than 6
months and those who perceived a lower likelihood of sur-
vival beyond the next 6 months reported more depressive
symptoms and greater anxiety, compared with men who
survived more than 6 months or who were more optimistic
about their prognosis. However, men who reported having
had a full prognostic discussion with their oncologist had less
depressive symptoms than men who reported having had no
or only brief prognostic discussions. The moderation analyses
demonstrated that among patients with poor perceived
FIG. 1. Overall survival from study enrollment.
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prognosis, having had a full prognostic discussion was asso-
ciated with less depression. Thus, prognostic discussions may
offer provide opportunities to ameliorate symptoms of de-
pression for men with advanced cancer.
The moderation analysis also demonstrated that men who
perceived a lower likelihood of survival at 6 months experi-
enced increased anxiety if the oncologist reported having
had a full discussion about prognosis. This is consistent with
prior observations that the manner in which the oncologist
conducts consultations correlate with patients’ levels of
anxiety.2,25–26 Of particular relevance is a study of initial
consultations between patients with advanced cancer and
their oncologists. Disclosure of prognostic information was
not predictive of anxiety immediately following the consul-
tation. However, oncologists’ encouragement of patient par-
ticipation in treatment decision making was correlated with
increased anxiety levels that persisted for at least 2 weeks.2
This raises the possibility that anxiety may result when on-
cologists’ communications are not congruent with patient
preferences for decision making. In the current study, in-
creased anxiety levels could have resulted from oncologists
providing information based on their own preferences rather
than those of the patient. This interpretation is supported by
results from a recent study that showed that patients with
advanced cancer who were anxious were also less comfort-
able asking questions.26
There are several potential limitations of this study. First,
the study was cross-sectional and causation cannot be in-
ferred. It is possible that men who were depressed or anxious
reported a more pessimistic prognosis as an expression of
their psychological state rather than the prognosis leading to
depressive symptoms or anxiety. In support of this conjecture,
Schofield reported that preferences for discussions of life
expectancy were correlated with increased symptoms of de-
pression as measured by the HADS.27 However, in this
study, relationships between patient-reported or oncologist-
reported extent of prognostic discussions and patients’ or
oncologists’ perceptions of life expectancy or actual 6-month
survival were not significant (data not shown). Furthermore,
the moderation of depression scores by patient-reported ex-
tent of prognostic discussions strongly suggests that per-
ceived prognosis led to anxiety or depression. It is difficult to
imagine how a prognostic discussion would improve de-
pressive symptoms if the patients’ perceptions of a poor
prognosis led to depression.
Second, we relied upon patient- or oncologist-recall and our
study was not designed to independently verify the accuracy of
the reported extent of prognostic discussions. However, we
specifically phrased the survey question to encompass both
life expectancy and discussions about what a person with
advanced-stage cancer may experience in the future to capture
a broader range of prognostic discussions. Results of the
Table 3. Interactions between Prognostic Discussions, Perceived Prognosis, and Depression or Anxiety
Interaction between patient-reported prognostic discussions and patient-perceived prognosis at 6 months on depression
Depression
N Mean SD P* ES
Full discussion
Patient-perceived prognosis, 6 months
> 90% (1) 18 2.3 1.9 0.188
‘‘ < 10%’’ through ‘‘about 75%’’ (2) 3 2.7 2.9
Don’t know (3) 6 4.3 3.1
None or brief discussion
Patient-perceived prognosis, 6 months




3.23‘‘ < 10%’’ through ‘‘about 75%’’ (2) 12 6.9 3.3
Don’t know (3) 10 2.7 2.5
Interaction between oncologist-reported prognostic discussion and patient-perceived prognosis at 6 months on anxiety
Anxiety
N Mean SD P*
Full discussion
Patient-perceived prognosis, 6 months
> 90% (1) 20 3.6 3.2 0.002
(2) > (1)
1.81
‘‘ < 10%’’ through ‘‘about 75%’’ (2) 7 9.4 3.5
Don’t know (3) 8 6.6 4.7
None or brief discussion
Patient-perceived prognosis, 6 months
> 90% (1) 33 5.6 3.5 0.444
‘‘ < 10%’’ through ‘‘about 75%’’ (2) 8 6.6 4.6
Don’t know (3) 8 4.4 2.1
ES denotes effect size. The effect size was determined with the use of Cohen’s d statistic; an effect size of 0.20 is small, 0.50 moderate, and
0.80 large. SD denotes standard deviation.
Values in bold are significant at p < .05
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prospective Coping with Cancer Study demonstrated that pa-
tients who reported they had discussed their wishes for end-of-
life care with their physicians received less aggressive medical
care, earlier hospice referral, and improved quality of life.17–18
Therefore, we conclude that patient self-report of prognostic
discussions seem to accurately reflect their experiences.
Third, the observed survival of participants after enroll-
ment was better than expected. However, the relatively fa-
vorable prognosis of these men may have weakened the
relationships between depression or anxiety and prognostic
discussions. Oncologists tend to delay discussions of prog-
nosis until there are no further treatments.4 Thus, the rela-
tionship between oncologist-reported prognostic discussions
and anxiety might have been stronger if participants were
closer to death. Fourth, the results may only apply to Cau-
casian men due to the low number of other races. Finally, we
did not assess for physical symptoms, which may have con-
tributed to depression,28–29 although a relationship between
physical symptoms and anxiety or depression is not uni-
formly observed.30
There are several strengths of this study. First, we recruited
men with advanced cancer who were still receiving care di-
rected by a medical oncologist. Thus, prognostic discussions
remained highly relevant for treatment decision making for
the enrolled cohort. Studies of patients enrolled on palliative
care or hospice likely reflect a group of people who have ac-
cepted their prognosis and decided against further chemo-
therapy.9,31 Second, there was a high rate of enrollment and
completion of surveys. Third, frequency of probable or defi-
nite anxiety disorder or depression was in the range reported
in larger studies of patients with cancer.32,33 Fourth, as an-
ticipated, the patients were quite optimistic about their life
expectancy. This finding is consistent with the observation
that most individuals tend to be overly optimistic across
multiple domains.34 Further empiric research is required to
determine the extent to which patient personality (e.g., trait
hope or optimism) accounts for the observed variance in
prognostic estimates. Thus, our results are likely applicable to
other men with advanced cancer.
In conclusion, the findings of this study enrich our under-
standing of the complicated relationships among anxiety or
depression, perceived prognosis, and prognostic discussions
among men with advanced cancer. Depressive symptoms were
lower in men who perceived a poor prognosis and reported
having had a full prognostic discussion with their oncologist.
We also observed higher levels of anxiety when oncologists
reported having had a full prognostic discussion. These results
demonstrate the need to differentiate anxiety and depression.
Anxiety stems from perception of a possible, though uncertain,
threat; depression stems from perception of past or unavoid-
able future loss.35 An implication of this distinction is that,
although both anxiety and depression are unpleasant, anxiety
may serve as a useful cue for oncologists, indicating the need to
clarify patient preferences for information and decision making
as a means to facilitate positive adjustment.36 These results
strongly suggest that prognostic discussions are more helpful,
than harmful, to men with advanced cancer.
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